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Evidence based perioperative care
has resulted in an average reduction in length of stay of 2.5 days and a
decrease in complications by as much as 50% for patients undergoing
colorectal surgery [1,2]. These beneﬁts are achieved by reducing surgical
stress, maintaining normal physiological function postoperatively, and
enhancing mobilization after surgery [3]. Furthermore, use of ERP has
resulted in amean savings of $2245 (1651€) per patient [4]. ERAS®pro-
tocols have been published for rectal, urological, pancreatic and gastric
surgeries [5–8]. Given the proven beneﬁt to both the patient and the
healthcare system, several international groups are currently working
with the ERAS® Society to develop protocols speciﬁc for breast and re-dissimilarities among the protocols and highlighted the need to develop1. Introduction
The systematic implementation of an evidence-based perioperative
care protocol (or “enhanced recovery pathway,” ERP), such as that31 29th StNW, Calgary, Alberta
. This is an open access article under
idelines for pre- and intra-ope
l (2015), http://dx.doi.org/10constructive surgery, head and neck cancer, thoracic, hepatobiliary, and
orthopedic surgery.
A recent review of ERP in gynecologic oncology [9] showed marked
a standardized, evidence-based guideline for our specialty. Standardiz-
ing perioperative care helps to ensure that all patients receive optimal
treatment and is required to measure compliance. Auditing compliance
has proven to be a key factor to successfully implement and sustain an
ERAS®protocol. The goal of this article is to critically review existing ev-
idence and make recommendations for elements of pre- and intra-
operative care in our specialty. This effort forms the basis of the
ERAS®Guideline for pre- and intra-operative care in gynecologic/oncol-
ogy surgery.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Literature search
The authors convened in July 2014 to discuss topics for inclu-
sion — the topic list was based on the ERAS® colonic surgery [1]
and rectal/pelvic [5] guidelines which were used as templates.
After the topics were agreed upon they were then allocated
among the group according to expertise. The literature search
(1966–2014) used Embase and PubMed to search medical subject
headings including “gynecology”, “gynecologic oncology” and all
pre- and intra-operative ERAS® items (see Table 1). Reference
lists of all eligible articles were crosschecked for other relevant
studies.
2.2. Study selection
Titles and abstracts were screened by individual reviewers to
identify potentially relevant articles. Discrepancies in judgment
were resolved by the lead (GN) and senior authors (OL, SD). Meta-
analyses, systematic reviews, randomized controlled studies, non-
randomized controlled studies, reviews, and case series were consid-
ered for each individual topic.Table 1
Guidelines for pre- and intraoperative care in gynecologic/oncology surgery: Enhanced Recove
Item Recommendation
Preoperative information education and
counseling
Patients should routinely receive dedicated pre
Preoperative optimization Smoking and alcohol consumption (alcohol ab
weeks before surgery
Anemia should be actively identiﬁed, investiga
Preoperative bowel preparation Mechanical bowel preparation should not be u
resection is planned
Preoperative fasting and carbohydrate
treatment
Clear ﬂuids should be allowed up to 2 h and so
induction of anesthesia
Carbohydrate loading reduces postoperative insu
routinely
Preanesthetic medication Routine administration of sedatives to reduce
avoided
Thromboembolism prophylaxis Patients at risk of VTE should receive prophyla
commenced preoperatively, combined with m
Patients should be advised to consider stoppin
preparations before surgery
Patients should discontinue oral contraception pr
form
Antimicrobial prophylaxis and skin
preparation
IV antibiotics (1st generation cephalosporin or
administered routinely within 60 min before sk
be given during prolonged operations, severe b
Hair clipping is preferred if hair removal is ma
Chlorhexidine–alcohol is preferred to aqueous po
cleansing
Standard anesthetic protocol Short acting anesthetic agents should be used
A ventilation strategy using tidal volumes of 5–
should be employed to reduce postoperative p
Postoperative nausea and vomiting A multimodal approach to PONV with N2 antie
patients undergoing gynecologic procedures
Minimally invasive surgery (MIS) MIS is recommended for appropriate patients
available
Nasogastric intubation Routine nasogastric intubation should be avoid
Nasogastric tubes inserted during surgery should
anesthesia
Preventing intraoperative hypothermia Maintenance of normothermia with suitable a
used routinely
Perioperative ﬂuid management Very restrictive or liberal ﬂuid regimes should
In major open surgery and for high risk patien
(N7 ml/kg) or a SIRS response the use of advan
facilitate individualized ﬂuid therapy and optim
perioperative period is recommended
Please cite this article as: G. Nelson, et al., Guidelines for pre- and intra-ope
Surgery (ERAS®) Society rec..., Gynecol Oncol (2015), http://dx.doi.org/102.3. Quality assessment and data analyses
The quality of evidence and recommendations were evaluated
according to the Grading of Recommendations, Assessment, Develop-
ment and Evaluation (GRADE) system (see Tables 2a and 2b) [10]
whereby recommendations are given as follows: Strong recommenda-
tions indicate that the panel is conﬁdent that the desirable effects of ad-
herence to a recommendation outweigh the undesirable effects. Weak
recommendations indicate that the desirable effects of adherence to a
recommendation probably outweigh the undesirable effects, but the
panel is less conﬁdent. Recommendations are based on quality of evi-
dence: high, moderate, low and very low, but also on the balance be-
tween desirable and undesirable effects. As such, consistent with other
ERAS® Guideline Working groups [1,6], in some cases strong recom-
mendations may be reached from low-quality data and vice versa. Of
note, this would be considered a modiﬁed GRADE evaluation since we
did not consider resource utilization when making our recommenda-
tions [11].
3. Results
The evidence base, recommendations, evidence level, and recom-
mendation grade are provided for each individual ERAS® item below.ry After Surgery (ERAS®) Society recommendations.
Evidence level Recommendation
grade
operative counseling Low Strong
users) should be stopped four Smoking: High Strong
Alcohol: Moderate Strong
ted, and corrected preoperatively High Strong
sed routinely even when bowel Moderate Strong
lids up to 6 h hours prior to Solids/ﬂuids: High Strong
lin resistance and should be used Carb loading: Mod
(outcome insulin
resistance)
Carb loading: Mod
(other outcomes)
Strong
anxiety preoperatively should be Low Strong
xis with either LMWH or heparin,
echanical methods
High (Preop admin: Mod) Strong
g HRT or consider alternative Low Weak
ior to surgery and switch to another High Strong
amoxi–clav) should be
in incision; additional doses should
lood loss and obese patients
High Strong
ndatory High Strong
vidone-iodine solution for skin High Strong
to allow rapid awakening Low Strong
7 ml/kg with a PEEP of 4–6 cm H2O
ulmonary complications
Moderate Strong
metic agents should be used for Moderate Strong
when expertise and resources are Morbidity: Low
Recovery: High
Strong
ed High Strong
be removed before reversal of
ctive warming devices should be High Strong
be avoided in favor of euvolemia High Strong
ts where there is large blood loss
ced hemodynamic monitoring to
ize oxygen delivery during the
Moderate Strong
rative care in gynecologic/oncology surgery: Enhanced Recovery After
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Table 2a
GRADE system for rating quality of evidence.
Evidence level Deﬁnition
High quality Further research unlikely to change conﬁdence in estimate
of effect
Moderate quality Further research likely to have important impact on
conﬁdence in estimate of effect and may change the
estimate
Low quality Further research very likely to have important impact on
conﬁdence in estimate of effect and likely to change the
estimate
Very low quality Any estimate of effect is very uncertain
Ref. [10].
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Preoperative counseling helps to set expectations about surgical and
anesthetic procedures andmay diminish fear, fatigue, pain, and enhance
recovery and early discharge [12]. Verbalized education, leaﬂets, and
multimedia information containing explanations of the procedure and
cognitive interventions may improve pain control, nausea and anxiety
after surgery [13]. It is uncertain if formal education is superior to infor-
mal education [14], but ideally patients should receive information in
both written and oral form. The patient and a relative or care provider
should meet with all members of the team including the surgeon, anes-
thetist and nurse. Studies show that patients with gynecologic cancer
prefer to bewell informed, and support from a nurse at the time of diag-
nosis reduced stress levels for up to 6 months [15].
Summary and recommendation:
Although quality evidence is lacking, most studies show that
counseling provides beneﬁcial effects with no evidence of harm. It
is recommended that patients should routinely receive dedicated
preoperative counseling.
Evidence level:
Low.
Recommendation grade:
Strong.
3.2. Preadmission optimization
Use of tobacco, alcohol, and the presence of anemia should be
routinely assessed preoperatively. Also, previously undiagnosed diabe-
tes/hyperglycemic states are becoming increasingly common. Evidence
that interventions addressing these factors prior to elective surgery
reduce perioperative morbidity and mortality is presented below. For
patients with gynecologic cancer, the risk of delaying surgery in order
to complete preoperative optimization must be carefully considered.
3.2.1. Smoking
Smoking is associated with a high risk of postoperative complica-
tions, but the pulmonary effects of smoking can be improved within
four weeks of cessation [16]. While smoking cessation interventions
such as behavioral support and nicotine replacement therapy are
known to result in short term smoking cessation, there isweak evidenceTable 2b
GRADE system for rating strength of recommendations.
Recommendation
strength
Deﬁnition
Strong When desirable effects of intervention clearly outweigh the
undesirable effects, or clearly do not
Weak When trade-offs are less certain — either because of low
quality evidence or because evidence suggests desirable and
undesirable effects are closely balanced
Ref. [10].
Please cite this article as: G. Nelson, et al., Guidelines for pre- and intra-ope
Surgery (ERAS®) Society rec..., Gynecol Oncol (2015), http://dx.doi.org/10to show that these measures decrease postoperative morbidity. A trial
of varenicline showed an increase in long term smoking cessation but
no evidence of a reduction in postoperative morbidity [17].3.2.2. Alcohol
The chronic effects of alcohol on the liver, pancreas and neurologic
system are well known. In the perioperative period, effects of alcohol
on cardiac function, blood clotting, immune function, and response to
surgical stress contribute to excessmorbidity. Intensive preoperative in-
terventions aimed at complete alcohol cessation for at least four weeks
reduces postoperative complications, but does not signiﬁcantly reduce
mortality or length of stay. However, only a small number of studies
are available, the mechanism by which such interventions reduce com-
plications is unknown, and the optimal timing of the interventions has
yet to be determined [18].3.2.3. Preoperative hyperglycemia
A report by the American Society of Anesthesiologists in 2012 noted
that up to 40% of preoperative patients may have an abnormal blood
glucose level and of the 13% with diabetes, 40% were undiagnosed
[19]. For the group with previously unrecognized hyperglycemia, the
risk of adverse perioperative events was higher than the risks for pa-
tients with a known diagnosis of diabetes [20]. In a small study of 120
patients undergoing colorectal surgery, elevated hemoglobin A1c
(HbA1c)was associated with an increased risk of postoperative compli-
cations [21]. The beneﬁt of tight glycemic control has not been shown
conclusively but the authors of one review suggest that “it seems pru-
dent to control blood glucose to a reasonable level preoperatively”,
while acknowledging that “recommendations for exact targets cannot
bemade” [22]. The results of a number of studies on tight glycemic con-
trol (TGC) are contradictory. Complicated and variable protocols are
used to achieve glycemic control, the duration of TCG varies between
studies, and there are persistent concerns with hypoglycemia. Delaying
surgery to correct hyperglycemia has not been shown to improve surgi-
cal outcomes in existing larger observational datasets [23].3.2.4. Anemia
Preoperative anemia is associatedwith postoperative morbidity and
mortality. A comprehensive reviewof bloodmanagement in Europe and
theNHSBlood TransfusionCommitteeGuidelines in theUK advocate for
preoperative screening for anemia. Anemia should be identiﬁed and
corrected for iron deﬁciency and any underlying disorder before elec-
tive surgery [24]. Treating anemia preoperatively helps to avoid adverse
effects from anemia, transfusion or both. The risks are increased with
the severity of the anemia [25]. The speed of response to iron therapy
(oral or intravenous) is greater in more severe iron deﬁciency anemia
and therefore prompt identiﬁcation and treatment is important to
reduce the need for erythropoiesis-stimulating agents or transfusion.
Although not gynecological-cancer speciﬁc, both erythropoiesis-
stimulating agents and perioperative transfusion have been associated
with poorer outcomes for cancer patients, with a Cochrane review
showing an increase in cancer recurrence following perioperative trans-
fusion [26,27].
The recent guideline from the British Committee for Hematology
showed no strong evidence of beneﬁt from preoperative transfusion
to improve surgical outcomes (in cardiac surgery patients) and, in the
absence of other blood management measures, did not reduce total
transfusion requirements. Where transfusion is considered to be
unavoidable there is no evidence to suggest advantages of pre- over
intraoperative transfusion [25]. If possible, the focus should be on
preventing further blood loss intraoperatively.
Summary and recommendations:
Smoking is associated with increased postoperative morbidity and
should be stopped at least four weeks before surgery.rative care in gynecologic/oncology surgery: Enhanced Recovery After
.1016/j.ygyno.2015.11.015
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mortality and should be avoided for at least four weeks before surgery
in patients who abuse alcohol.
Anemia is associated with an increase in postoperative morbidity
and mortality and should be identiﬁed, investigated, and corrected
preoperatively. Iron therapy is the preferred ﬁrst line treatment for
the correction of iron deﬁciency anemia.
Evidence level:
Smoking: High.
Alcohol: Moderate (small number of studies).
Anemia: High.
Recommendation grade:
Smoking: Strong.
Alcohol: Strong.
Anemia: Strong.
3.3. Preoperative mechanical bowel preparation
Mechanical bowel preparation (MBP) often results in patient dis-
tress, may cause dehydration, and evidence of beneﬁt to the patient is
lacking. A systematic review of 18 randomized clinical trials (5805 pa-
tients) found no statistically signiﬁcant evidence that patients beneﬁt
from either bowel preparation or rectal enemas [28] — the infection
and anastomotic leak rates in patients with a bowel preparation was
9.6% and 4.4%, respectively, compared to 8.5% and 4.5% for those with-
out. The authors concluded that in colonic surgery, bowel cleansing
may be safely omitted. Recently, a number of large retrospective studies
have suggested that oral antibiotic bowel preparationmay be associated
with decreased infection rates [29]. This, however, has not been veriﬁed
in randomized trials investigating oral antibiotics alone (without MBP)
in sufﬁcient numbers of patients. There is some debate currently as to
the beneﬁt of bowel preparation in patients undergoing low anterior re-
section. In a single-blind, RCT of rectal cancer patients undergoing low
anterior resection, patients were randomized to preoperative MBP ver-
sus no preparation [30]. Overall and infectiousmorbiditywere higher in
the no MBP group. However, there was no signiﬁcant difference in the
rate of anastomotic leakage between groups. Further studies are
required in this area.
Finally, the routine use ofmechanical bowel preparation beforemin-
imally invasive gynecologic surgery has not been shown to improve in-
traoperative visualization, bowel handling, or ease of performing the
procedure [31–33].
Summary and recommendation:
Routine oral mechanical bowel preparation should not be used in
gynecologic/oncology surgery, including patients with a planned enter-
ic resection.
Evidence level:
Moderate (extrapolated from results in colorectal patients).
Recommendation grade:
Strong.
3.4. Preoperative fasting and carbohydrate treatment
Scientiﬁc evidence has shown that intake of clear ﬂuids until 2 h be-
fore surgery does not increase gastric content, reduce gastric ﬂuid pH, or
increase complication rates. Hence, in patients without conditions asso-
ciated with delayed gastric emptying, the intake of clear ﬂuids until 2 h
before the induction of anesthesia as well as a 6 h fast for solid food is
now recommended [34].
In order to reduce postoperative insulin resistance and associated in-
creased risks for complications, carbohydrate loadingbefore surgery has
been advocated to achieve a metabolically fed state. In the last decade
an increasing number of original studies, systematic reviews, and
meta-analyses have shown that carbohydrate loading attenuates the in-
crease in insulin resistance related to surgery, and hence should be used
routinely in major abdominal surgery [1,35]. Carbohydrate drinks forPlease cite this article as: G. Nelson, et al., Guidelines for pre- and intra-ope
Surgery (ERAS®) Society rec..., Gynecol Oncol (2015), http://dx.doi.org/10preoperative use should be properly tested as not all carbohydrate
drinks have the same effects on gastric emptying. Although no studies
have been performed in patients undergoing major gynecological sur-
gery, these ﬁndings are considered valid for gynecologic patients
given similarities in patient characteristics. Randomized trials have
demonstrated that preoperative carbohydrates improve wellbeing and
reduce nausea and vomiting [36]. No studies have speciﬁcally addressed
diabetic patients, although limited data indicate it is likely to be safe in
well controlled diabetics.
Summary and recommendation:
Patients should be permitted to drink clear ﬂuids until 2 h before an-
esthesia and surgery.
Patients should abstain from solids 6 h prior to induction of
anesthesia.
Oral carbohydrate loading reduces postoperative insulin resistance,
improves preoperative wellbeing, and should be used routinely.
Insufﬁcient data is available for diabetic patients.
Evidence level:
Solids and ﬂuids: High.
Carbohydrate loading, primary outcome insulin resistance: Moderate.
Carbohydrate loading other outcomes: Moderate.
Recommendation grade:
Fasting guidelines: Strong.
Carbohydrate loading: Strong.
3.5. Preanesthetic medication
Preoperative medications are widely used in major gynecological
surgery to decrease anxiety. However, routine administration of long-
acting sedatives within 12 h of surgery should be avoided due to its
effects on immediate postoperative recovery [37]. In 2009, a Cochrane
review of short-acting oral anxiolytics for outpatient surgery concluded
that patients were successfully discharged. However, an impairment in
psychomotor functionwas observed in some studies up to 4 h postoper-
atively, which may negatively inﬂuence the patient's ability to ambu-
late, eat and drink [37]. The use of short acting anxiolytics to address
severe preoperative anxiety may be appropriate on a case by case basis.
Summary and recommendation:
Routine administration of sedatives to reduce anxiety preoperatively
should be avoided in order to hasten postoperative recovery.
Evidence level:
Low.
Recommendation grade:
Strong.
3.6. Thromboembolism prophylaxis
Venous thromboembolism (VTE) is a major risk in gynecologic on-
cology patients with rates as high as 8% in endometrial cancer [38]
and 38% in ovarian cancer [39]. An analysis from the Million Women
study showed an increased risk of VTE 12 weeks postoperatively, with
a risk of 1/85 for oncologic surgery and 1/365 for gynecologic surgery
[40]. Patients undergoing oncologic surgery were at over 90 times the
risk of VTE in the ﬁrst 6 weeks. All gynecologic oncology patients with
major surgery N30 min should receive VTE prophylaxis with either
low molecular weight heparin (LMWH) or heparin [41]. Prophylaxis
should be commenced preoperatively, combined with mechanical
methods, and continued post-operatively [42].
3.6.1. Preoperative anticoagulation
Only one retrospective study has examined preoperative versus
postoperative anticoagulation in gynecologic oncology, showing a
decreased rate of DVT (8% vs. 1.9%; p = 0.04) and a decreased rate of
DVT associated deaths (0 vs. 2; p b 0.001) when given preoperatively;
all patients in this study received combined prophylaxis with medical
and mechanical methods [43].rative care in gynecologic/oncology surgery: Enhanced Recovery After
.1016/j.ygyno.2015.11.015
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Prophylactic anticoagulation has not been shown to increase risks of
hemorrhage, thrombocytopenia or epidural hematoma. Low dose pro-
phylactic heparin has been commonly used with less than 10 cases of
reported spinal hematomas; however given the serious sequelae associ-
ated with spinal hematomas, epidural catheters and spinal anesthetics
should not be placed or removed 12 h before or after the last dose of
therapeutic heparin [44].
Pneumatic compression stockings reduce the rate of VTEwhen com-
pared to observation within the ﬁrst 5 days postoperatively [45]. Their
efﬁcacy is equivalent to heparin [46] and improved when combined
with heparin [47] in gynecologic oncology patients.
3.6.3. Special circumstances
3.6.3.1. Hormone replacement therapy (HRT). A Cochrane review on long
term hormone therapy for perimenopausal and postmenopausal
women showed an elevated risk of thromboembolism in women treat-
ed with continuous combined HRT or estrogen used alone [48]. Extrap-
olating from this evidence, the use of HRT is viewed as a perioperative
risk factor for thromboembolism [49]. In the United Kingdom both the
National Institute for Health and Clinical Excellence (NICE) and the
Royal College of Obstetricians and Gynecologists (RCOG) suggest that
patients discontinue HRT 4 weeks before surgery, but stop short of a di-
rect recommendation [50,51]. These recommendations acknowledge
the paucity of direct evidence of HRT as a risk factor and emphasize
the importance of discussing the risks and beneﬁts of stopping HRT.
Changing from an oral to a transdermal estrogen preparation may re-
duce thromboembolic risk; of note, most patients taking HRT will
meet criteria to receive thromboprophylaxis.
3.6.3.2. Combined oral hormonal contraception. Combined oral hormonal
contraception is a risk factor for postoperative thromboembolism. The
risk of thromboembolism varies according to progesterone type, with
levonorgestrel, norethisterone, and norgestimate associated with the
lowest risk. Women should be encouraged to use an alternative form
of contraception preoperatively. Continued use of combined oral hor-
monal contraception is an indication for thromboprophylaxis [50,51].
Summary and recommendation:
Patients at risk of VTE should receive prophylaxiswith either LMWH
or heparin, commenced preoperatively, combined with mechanical
methods, and continued post-operatively.
HRT is a relative risk factor for postoperative thromboembolism and
patients should be advised to consider stopping or switching to alterna-
tive preparations before surgery, taking into account the risks and ben-
eﬁts. If HRT is continued, thromboprophylaxis should be considered.
Combined oral hormonal contraception is a risk factor for thrombo-
embolism. Patients should change to another form of contraception
prior to surgery. If continued to the time of surgery, thromboprophylaxis
should be prescribed.
Evidence level:
Stockings, pneumatic compression, LMWH: High.
Preoperative administration: Moderate.
HRT: Low.
Combined oral hormonal contraception: High.
Recommendation grade:
Pre-operative DVT prophylaxis: Strong.
HRT: Weak.
Combined oral hormonal contraception: Strong.
3.7. Antimicrobial prophylaxis and skin preparation
Most surgical interventions for gynecologic malignancies include
total hysterectomy which is classiﬁed as a clean contaminated, or type
II incision. Surgical site infections (SSI) in gynecology involve skin
ﬂora, vaginal ﬂora, or enteric bacteria when the colon is entered.Please cite this article as: G. Nelson, et al., Guidelines for pre- and intra-ope
Surgery (ERAS®) Society rec..., Gynecol Oncol (2015), http://dx.doi.org/10Prophylactic antibiotics should therefore be broad spectrum. Many
studies and meta-analyses have demonstrated the beneﬁts of antibiotic
prophylaxis in reducing surgical site infection after vaginal or abdomi-
nal hysterectomy [52]. Cephalosporins are the most commonly recom-
mended antibiotic class given their broad spectrum, low cost, and low
allergenic potential [53]. Cefazolin is generally recommended for gyne-
cologic interventionswhere antibiotic prophylaxis ismandatory. Amox-
icillin–clavulanic acid has been shown to be equivalent to cefazolin and
can also be used [54]. Antibiotics are administered intravenously within
1 h [55] before skin incision (usually at the time of anesthesia induc-
tion). The dose should be increased in obese patients (BMI N 35 or
N100 kg) [56], and repeated after 1–2 times the half-life of the chosen
medication in prolonged operations (eg. 3 h for cefazolin, half-life:
1.8 h) and in case of blood loss N1500 ml [57]. For patients allergic to
penicillin/cephalosporin, a combination of clindamycin and gentamycin
IV or a quinolone (eg. ciproﬂoxacin) can be used. Laparoscopic opera-
tions not contaminated by the genitourinary or digestive tracts do not
require antimicrobial prophylaxis [58].
Skin preparation before surgery traditionally includes a shower, hair
removal and the use of skin antiseptic solution. One Cochrane review
addressed the topic of showeringor bathingwith different antiseptic so-
lutions before surgery [59]. Showering using plain soap is as effective as
chlorhexidine in reducing surgical site infection. Compared to shaving,
hair clipping in the operating room immediately prior to surgery is asso-
ciated with lower rates of SSI [60]. However, there is no clear evidence
that hair removal reduces SSI, irrespective of the method chosen
(shaving, hair clipping or depilatory cream). Therefore, hair removal
should be avoided and if deemed necessary hair clipping is preferred.
Skin antiseptic is highly recommended. A RCT showed a 40% re-
duction in SSI when using chlorhexidine gluconate and isopropyl al-
cohol 70% compared to an aqueous solution of 10% povidone-iodine
for skin cleansing in different clean-contaminated interventions
[61]. Chlorhexidine–alcohol therefore is preferred over aqueous
povidone-iodine solution although care must be taken to avoid igni-
tion when electrocautery is used [62].
Summary and recommendation:
IV antibiotics should be administered routinelywithin 60min before
skin incision. The dose should be repeated in case of prolonged opera-
tions or severe blood loss and increased in obese patients.
Hair clipping is preferred if hair removal is mandatory.
Chlorhexidine–alcohol is preferred to aqueous povidone-iodine
solution for skin cleansing.
Evidence level:
Antibiotic prophylaxis: High.
Hair clipping: High.
Chlorhexidine–alcohol: High.
Recommendation grade:
Antibiotic prophylaxis: Strong.
Hair clipping: Strong.
Chlorhexidine–alcohol: Strong.
3.8. Standard anesthetic protocol
To allow rapid awakening, anesthesia should be maintained with
short-acting agents such as sevoﬂurane or desﬂurane, or continuous tar-
get controlled infusions of propofol. When combined with short-acting
opioid analgesics such as remifentanil, this may allow a consistently
rapid recovery. Propofol-based total intravenous anesthesia has fewer
postoperative side effects and the advantage of producing less postoper-
ative nausea and vomiting [63]. Nitrous oxide is associatedwith postop-
erative nausea and vomiting (PONV)when the baseline risk of vomiting
is high [64]. Both laparoscopic procedures and gynecological surgery are
independent predictors of PONV [65], so it is reasonable to omit N2O
during laparoscopic gynecologic surgery to prevent PONV and prophy-
laxis with a combination of at least 2 antiemetics should be standard.
Use of bispectral index (BIS) to guide anesthetic depth may allowrative care in gynecologic/oncology surgery: Enhanced Recovery After
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Regional anesthetic techniques are opioid sparing, reducing PONV and
allowing more rapid awakening [67]. Recent studies have shown a
reduction in pulmonary complications in patients undergoing open ab-
dominal surgery when a lung protective ventilation strategy is utilized
(TV5-7 ml/kg with PEEP 4–6 cm H2O) [68].
Summary and recommendation:
Short acting anesthetic agents should be used to allow rapid awak-
ening. The addition of regional anesthesia to general anesthesia is opioid
sparing, helps reduce PONV, and allows more rapid awakening.
A ventilation strategy using tidal volumes of 5–7 ml/kg with a PEEP
of 4–6 cm H2O reduces postoperative pulmonary complications.
Evidence level:
Short acting general anesthesia: Low (lack of data).
Lung protective ventilation (5–7 ml/kg): Moderate.
Recommendation:
Short acting general anesthesia: Strong.
Lung protective ventilation: Strong.3.9. Prevention of postoperative nausea and vomiting
Postoperative nausea and vomiting (PONV) is very common and
troubling for patients undergoing gynecologic surgery. Vomiting oc-
curs in 12–30% and nausea in 22–80% [69], potentially leading to
prolonged hospitalization and distress. Several risk factors have
been identiﬁed for PONV including: age b50 years, gynecologic sur-
gery, laparoscopic surgery, female gender, history of PONV ormotion
sickness, non-smoking, use of volatile anesthetics, long duration of
anesthesia, postoperative opioid use, obesity, and use of nitrous
oxide [65,69]. A patient's risk of PONV may be assessed using a vali-
dated risk score [69,70], allowing the clinician to give prophylaxis to
patients deemed to be at high risk.
Strategies for reducing PONV include administration of antiemetic
prophylaxis to all patients receiving abdominal surgery and emetogenic
anesthetics/analgesics; this would likely include a large proportion of
gynecologic or gynecologic oncology patients. The second strategy is
to decrease PONV risk by avoiding general anesthesia, using propofol in-
fusions, avoiding nitrous oxide and volatile anesthetics, reducing opioid
use, and decreasing the neostigmine dose [69,71]. Although regional in-
terventions (e.g. transversus abdominis plane block) may decrease opi-
oid use and postoperative pain, this may not directly translate into a
PONV advantage in all cases [72].
A multimodal approach to PONV prevention is quickly becoming
standard of care. Antiemetics are classiﬁed into the following catego-
ries: 5HT3 antagonists, NK-1 antagonists, corticosteroids, butyrophe-
nones, antihistamines, anticholinergics and phenothiazines [69,73].
Combinations of two or more classes of antiemetics may enhance
potency (e.g. aprepitant, ondansetron, midazolam, or haloperidol com-
bined with dexamethasone) [69,74–77]. Although dexamethasone has
good efﬁcacy for PONV and pain control, its long term effects as an im-
munosuppressant are unknown [69]. If nausea and vomiting occurs
postoperatively, an antiemetic drug from a different class should be
selected. A 5-HT3 antagonist should be administered ﬁrst since it is
the only category that has been well studied for existing PONV [69,77,
78]. Transdermal scopolamine has also been shown to decrease the
rate of PONV with application the night before or on the same day as
surgery [79].
Supplemental oxygen may reduce the risk of early vomiting, but
has no overall effect on PONV, and is therefore no longer recom-
mended for the prevention of PONV [69,79]. P6 acupoint stimulation
has also been shown to decrease PONV regardless of timing of
administration [80]. Other therapies including music therapy, iso-
propyl alcohol, aromatherapy, ginger, NG decompression, proton
pump inhibitor and nicotine patches have been proposed, but are
not supported by current evidence [69,81–85]. Alternative non-Please cite this article as: G. Nelson, et al., Guidelines for pre- and intra-ope
Surgery (ERAS®) Society rec..., Gynecol Oncol (2015), http://dx.doi.org/10pharmacologic therapies are not commonly used due to difﬁculties
with access and efﬁcacy of existing drug therapies.
Summary and recommendations:
Patients undergoing gynecologic procedures should receive prophy-
laxis using a multimodal approach to PONV using more than two anti-
emetic agents.
The risk of PONV is reduced with increased utilization of regional
anesthesia, decreasing or eliminating opioids, neostigmine, volatile
anesthetics, and increasing propofol use.
Evidence level:
Moderate.
Recommendation grade:
Strong.
3.10. Minimally invasive surgery
The introduction of laparoscopy and, more recently, robotic surgery,
has led to substantial improvements in patient outcomes by decreasing
intraoperative blood loss, length of stay, analgesic requirements, return
of bowel function, length of hospitalization, and return to normal daily
activities [86,87]. However, the perioperative beneﬁts of this approach
may be reduced by a number of elements, including uncontrolled
pain, nausea and vomiting, ﬂuid overload, limited ambulation, fatigue,
and deconditioning, irrespective of the existence of postoperative com-
plications. Age, blood loss, perioperative blood transfusion, and postop-
erative complications have been associated with prolonged length of
stay after laparoscopic surgery [88].
While most investigations of ERAS programs have been performed
in open surgery, there is mounting evidence that ERAS programs are
also beneﬁcial for patients undergoing laparoscopic surgery. The LAFA
(LAparoscopy and/or FAst track multimodal management vs. standard
of care) trial evaluated patients requiring segmental colectomy for
colon cancer. The study included four arms (laparoscopy/ERAS vs. lapa-
roscopy/traditional vs. open/ERAS vs. open/traditional). The investiga-
tors in this study concluded that the optimal perioperative treatment
for patients requiring segmental colectomy for colon cancer was laparo-
scopic resection in combination with an ERAS program [89]. Further-
more, several reports have shown that implementation of an ERAS
program may also be of beneﬁt in the setting of vaginal hysterectomy,
including a shorter length of hospital stay and higher patient satisfac-
tion scores [90,91].
Elements of particular value for an ERAS program in minimally
invasive surgery include avoidance of prolonged nasogastric intu-
bation (see Nasogastric intubation, below), maintenance of nor-
mothermia, normovolemia with maintenance of adequate cardiac
output (impacted in minimally invasive surgery by head-down
position and pneumoperitoneum), prevention of postoperative
ileus, and early mobilization [1].
Summary and recommendation:
Minimally invasive surgery (MIS), including vaginal surgery is
preferred for appropriate patients when feasible.
Evidence level:
Morbidity: Low.
Recovery: High.
Recommendation grade:
Strong.
3.11. Nasogastric intubation
Meta-analyses have concluded that nasogastric intubation increases
the risk of postoperative pneumonia (6% vs. 3%) after elective abdomi-
nal surgery. Moreover, nasogastric decompression does not reduce the
risk of wound dehiscence or intestinal leaks [92]. In a prospective ran-
domized trial comparing early feeding to nasogastric decompression
after major open gynecologic oncology surgery, the authors found no
signiﬁcant difference in postoperative nausea and vomiting betweenrative care in gynecologic/oncology surgery: Enhanced Recovery After
.1016/j.ygyno.2015.11.015
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tube insertion because of sub-occlusive symptoms. Conversely, 88% of
patients who had a nasogastric tube experienced moderate to severe
discomfort. Time to passage of ﬂatus or stools and length of hospital
stay was signiﬁcantly shorter in the early diet group [93].
One exception where gastric decompression by oro- or nasogastric
intubation may be of beneﬁt is during laparoscopic or robotic surgery,
whereby decompression may be used to reduce risk of gastric perfora-
tion by trochar or Veress needle insertion. The tube, however, should
be removed at extubation.
Summary and recommendation:
Routine nasogastric intubation should be avoided. Nasogastric
tubes inserted during surgery should be removed before reversal of
anesthesia.
Evidence level:
High.
Recommendation grade:
Strong.
3.12. Preventing intraoperative hypothermia
During anesthesia andmajor surgery there is a high risk of hypother-
mia due to exposure and impairment of the normal thermoregulatory
response, resulting in accelerated heat loss [94]. Hypothermia has
been shown to impair drug metabolism, adversely affect coagulation,
and increase bleeding, cardiac morbidity, and wound infection
[94–96]. Postoperative shivering also increases oxygen consumption
at a critical time and can worsen pain [95]. It is important to maintain
normothermia by active methods throughout the perioperative period,
including prewarming patients to avoid an initial drop in body temper-
ature [97].Wound infections are signiﬁcantly less commonwith the use
of activewarming compared to conventionalmethods, with an absolute
risk reduction of 13% [95]. During surgery, warming using forced air
blanket devices are effective andwidely used [98]. Underbodywarming
mattresses are also effective and avoid the use of a blanket that may in-
terfere with surgical access, particularly in robotic surgery [99]. Intrave-
nous ﬂuids should be warmed using a suitable device to avoid lowering
body temperature [100]. Temperature monitoring should be used to
guide therapy and to avoid hyperthermia, which also has deleterious
effects on homeostasis. Patients who have prolonged surgery with a
likelihood of a Systemic Inﬂammatory Response (SIRS), such as open
debulking procedures, are at a higher risk of developing hyperpyrexia
as surgery progresses if warming is notmonitored. Themost convenient
site to measure core temperature during gynecological surgery is the
nasopharynx. Warming should be continued into the postoperative
period to ensure the patient leaves the post anesthetic care unit with a
temperature N36.0 °C.
Summary and recommendation:
Patient temperaturemonitoring ismandatory to titratewarmingde-
vices and avoid hypo- and hyperpyrexia.Maintenance of normothermia
with suitable active warming devices should be used routinely.
Evidence level:
Continuousmeasurement of core temperature for efﬁcacy and com-
pliance: High.
Use of active warming devices: High.
Recommendation grade:
Strong.
3.13. Principles of perioperative ﬂuid balance
The aim of intravenous ﬂuid therapy is to maintain normovolemia
and reduce ﬂux across the extracellular space. Enhanced recovery pro-
tocols and modern surgical techniques reduce the need for both total
volume and duration of intravenous ﬂuid therapy [101]. While salt
and ﬂuid overload in the postoperative period is a major cause of mor-
bidity [102], very restrictive ﬂuid regimes also lead to increasedPlease cite this article as: G. Nelson, et al., Guidelines for pre- and intra-ope
Surgery (ERAS®) Society rec..., Gynecol Oncol (2015), http://dx.doi.org/10morbidity and mortality. There have been very few randomized trials
investigating ﬂuid therapy and hemodynamic monitoring in major
gynecologic surgery. Hence recommendations are based on extrapola-
tions from evidence in major intra-abdominal surgery. Patients under-
going colorectal resections randomized to a zero balance ﬂuid regimen
had fewer cardiopulmonary complications (7% vs. 24%; p b 0.001) com-
pared to standard perioperative ﬂuid management [103]. A meta-
analysis of 9 randomized trials from nearly 1000 patients demonstrated
that restrictive ﬂuid therapy reduced morbidity (OR 0.41; p = 0.005)
[104]. Importantly, these improvements in morbidity were not ob-
served ifﬂuid restrictionwas initiated only in the post-operative period.
Summary and recommendation:
Very restrictive or liberal ﬂuid regimes should be avoided in favor of
euvolemia.
Evidence level:
High.
Recommendation grade:
Strong.
3.14. Intraoperative ﬂuid therapy and advanced hemodynamic monitoring
Anesthetic drugs, intermittent positive pressure ventilation, and the
use of regional anesthetic techniques all have different effects on vaso-
motor tone causing arteriolar and venous dilatation leading to hypoten-
sion. Therefore, once intravascular volume is normalized during
surgery, vasopressors should beused tomaintainmean arterial pressure
when needed to avoid ﬂuid excess. Central venous catheters may be
needed to administer vasopressors and can be used in the immediate
post-operative period to guide ﬂuid administration by deriving oxygen
extraction from the SCVO2. The head down position and pneumo-
peritoneum used during MIS can cause difﬁculty in interpreting moni-
toring. The ﬂuid requirements during MIS in gynecology surgery are
reduced as compared with open surgery.
Arterial lines can be used to measure arterial blood gases giving im-
portant information about oxygenation, effective ventilation, blood pH,
and lactate as a marker for cellular perfusion. Dynamic changes in arte-
rial waveform derived values such as systolic pressure, pulse pressure
and stroke volume can be useful as predictors of ﬂuid responsiveness
[105], but when noradrenaline infusions are used the ﬂuid response
does not concur with the Esophageal Doppler Monitor (EDM) [106].
There have been two studies in gynecology patients within an ERP
using EDM. The ﬁrst showed minimal improvement, with a reduction
in length of stay from 7 to 6 days [107], but the second study showed
a beneﬁt in patients with advanced cancer including an earlier return
to gut function as well as reduced length of stay [108]. The beneﬁt
from the use of EDM in ﬁt elective patients undergoing uncomplicated
surgery within an ERAS Protocol is presently unclear [109] and regular
ﬂuid challenges in anaerobically ﬁt patients without an endpoint may
lead to harm [110]. High risk patients beneﬁt most from optimization
of oxygen delivery using inotropes in addition to ﬂuid [111].
Summary and recommendation:
Inmajor open surgery and for high-risk patients where there is large
blood loss (N7 ml/kg) or a SIRS response, the use of advanced hemody-
namicmonitoring to facilitate individualized ﬂuid therapy and optimize
oxygen delivery through the perioperative period is recommended.
Evidence level:
Moderate.
Recommendation grade:
Strong.
4. Discussion
This guideline outlines the recommendations of the ERAS Group for
the pre- and intraoperative management of patients undergoing gyne-
cologic and gynecologic oncology surgery, and is based on the best
available evidence. However, in some instances good quality data wasrative care in gynecologic/oncology surgery: Enhanced Recovery After
.1016/j.ygyno.2015.11.015
8 G. Nelson et al. / Gynecologic Oncology xxx (2015) xxx–xxxnot available for gynecologic/oncology patients. In these instances
recommendations were made based on ﬁndings from other surgical
disciplines, including colorectal surgery, in which major abdominal
surgery is routinely utilized. We are hopeful that individuals and
groups of surgeons will use these guidelines to help integrate
existing knowledge into practice, align perioperative care, and
encourage future investigations of optimal perioperative care for pa-
tients undergoing gynecologic/oncology surgery.
Conﬂict of interest statement
Dr. Acheson reports personal fees from Baxter UK Ltd., outside the submitted work. In ad-
dition, Dr. Acheson has a commercial (future royalties on a medical device in develop-
ment) relationship with Mediplus Ltd. He has also held the following appointments:
Joint National Clinical Advisor (Gynaecology) to the Enhanced Recovery Partnership Pro-
gramme, Department of Health (2010–2011), and continued under NHS Improvement
(2011–2013); Member of Steering Board, Enhanced Recovery ERAS (UK) (2011–2013).
Dr. Scott received honoraria for lecturing and travel expenses from Baxter Healthcare,
Merck, and Deltex. He is an Executive Committee member of the ERAS Society.
Dr. Ljungqvist has an appointment with Nutricia Advisory Board, has received speakers
honoraria from Nutricia, MSD, BBraun and Fresenius-Kabi. He is the current Chairman of
the ERAS Society (www.erassociety.org). He founded, serves on the Board and owns
stock in Encare AB that runs the ERAS Society Interactive Audit System (EIAS).
References
[1] U.O. Gustafsson, M.J. Scott, W. Schwenk, N. Demartines, D. Roulin, N. Francis, et al.,
Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery
After Surgery (ERAS) Society recommendations, World J. Surg. 37 (2) (2012)
259–284.
[2] M. Greco, G. Capretti, L. Beretta, M. Gemma, N. Pecorelli, M. Braga, Enhanced recov-
ery program in colorectal surgery: a meta-analysis of randomized controlled trials,
World J. Surg. 38 (6) (2014) 1531–1541.
[3] O. Ljungqvist, E. Jonathan, Rhoads lecture 2011: insulin resistance and enhanced
recovery after surgery, J. Parenter. Enter. Nutr. 36 (4) (2012 Jul) 389–398.
[4] M. Adamina, H. Kehlet, G.A. Tomlinson, A.J. Senagore, C.P. Delaney, Enhanced
recovery pathways optimize health outcomes and resource utilization: a meta-
analysis of randomized controlled trials in colorectal surgery, Surgery 6 (2011) 830.
[5] J. Nygren, J. Thacker, F. Carli, K.C. Fearon, S. Norderval, D.N. Lobo, et al., Guidelines for
perioperative care in elective rectal/pelvic surgery: Enhanced Recovery After Surgery
(ERAS) Society recommendations, World J. Surg. 37 (2) (2013 Feb) 285–305.
[6] Y. Cerantola, M. Valerio, B. Persson, P. Jichlinski, O. Ljungqvist, M. Hubner, et al.,
Guidelines for perioperative care after radical cystectomy for bladder cancer:
Enhanced Recovery After Surgery (ERAS®) Society recommendations, Clin. Nutr.
32 (6) (2013 Dec) 879–887.
[7] K. Lassen, M.M. Coolsen, K. Slim, F. Carli, J.E. de Aguilar-Nascimento, M. Schäfer,
et al., Guidelines for perioperative care for pancreaticoduodenectomy: Enhanced
Recovery After Surgery (ERAS®) Society recommendations, World J. Surg. 37 (2)
(2013 Feb) 240–258.
[8] K. Mortensen, M. Nilsson, K. Slim, M. Schäfer, C. Mariette, M. Braga, et al., Consensus
guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Sur-
gery (ERAS®) Society recommendations, Br. J. Surg. 101 (10) (2014 Sep) 1209–1229.
[9] G. Nelson, E. Kalogera, S.C. Dowdy, Enhanced recovery pathways in gynecologic
oncology, Gynecol. Oncol. 135 (3) (2014 Dec) 586–594.
[10] G.H. Guyatt, A.D. Oxman, G.E. Vist, R. Kunz, Y. Falck-Ytter, P. Alonso-Coello, et al.,
GRADE: an emerging consensus on rating quality of evidence and strength of rec-
ommendations, BMJ 336 (7650) (2008) 924–926.
[11] M. Brunetti, I. Shemilt, S. Pregno, L. Vale, A.D. Oxman, J. Lord, et al., GRADE guide-
lines: 10. Considering resource use and rating the quality of economic evidence, J.
Clin. Epidemiol. 66 (2) (2013 Feb) 140–150.
[12] L.D. Egbert, G.E. Battit, C.E. Welch, M.K. Bartlett, Reduction of postoperative pain by
encouragement and instruction of patients. A study of doctor–patient rapport, N.
Engl. J. Med. 270 (1964) 825–827.
[13] V. Ridgeway, A. Mathews, Psychological preparation for surgery: a comparison of
methods, Br. J. Clin. Psychol. 21 (Pt 4) (1982 Nov) 271–280.
[14] K.S. Gurusamy, J. Vaughan, B.R. Davidson, Formal education of patients about to
undergo laparoscopic cholecystectomy, Cochrane Database Syst. Rev. (2) (2014),
http://dx.doi.org/10.1002/14651858.CD009933.pub2 (Art. No.: CD009933).
[15] D.E. Stewart, F. Wong, A.M. Cheung, J. Dancey, M. Meana, J.I. Cameron, et al., Infor-
mation needs and decisional preferences among women with ovarian cancer,
Gynecol. Oncol. 77 (3) (2000 Jun) 357–361.
[16] L.T. Sorensen, Wound healing and infection in surgery: the pathophysiological im-
pact of smoking, smoking cessation, and nicotine replacement therapy: a system-
atic review, Ann. Surg. 255 (6) (2012) 1069–1079.
[17] T. Thomsen, N. Villebro, A.M. Møller, Interventions for preoperative smoking cessa-
tion, Cochrane Database Syst. Rev. (3) (2014) (Art no CD002294).
[18] K.Oppedal, A.M.Møller, B. Pedersen,H. Tønnesen, Preoperative alcohol cessation prior
to elective surgery, Cochrane Database Syst. Rev. (7) (2012) (Art no CD008343).
[19] J.L. Apfelbaum, R.T. Connis, D.G. Nickinovich, American Society of Anesthesiologists
Task Force on preanesthesia evaluation. Practice advisory for preanesthesia evalu-
ation: an updated report by the American Society of Anesthesiologists Task Force
on preanesthesia evaluation, Anesthesiology 116 (3) (Mar 2012) 522–538.Please cite this article as: G. Nelson, et al., Guidelines for pre- and intra-ope
Surgery (ERAS®) Society rec..., Gynecol Oncol (2015), http://dx.doi.org/10[20] M. Kotagal, R.G. Symons, I.B. Hirsch, G.E. Umpierrez, E.P. Dellinger, E.T. Farrokhi,
et al., Perioperative hyperglycemia and risk of adverse events among patients
with and without diabetes, Ann. Surg. 261 (1) (Jan 2015) 97–103.
[21] U.O. Gustafsson, A. Thorell, M. Soop, O. Ljungqvist, J. Nygren, Haemoglobin A1c as a
predictor of postoperative hyperglycaemia and complications after major colorec-
tal surgery, Br. J. Surg. 96 (2009) 1358–1364.
[22] A. Sheehy, R. Gabbay, An overview of pre-operative glucose evaluation, man-
agement, and perioperative impact, J. Diabetes Sci. Technol. 3 (6) (Nov 2009)
1261–1269.
[23] R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, H.A. Neil, 10-year follow-up of
intensive glucose control in type 2 diabetes, N. Engl. J. Med. 359 (15) (2008)
1577–1589.
[24] NHS Blood Transfusion Committee, Patient blood management — an evidence-
based approach to patient care, http://www.transfusionguidleines.org.uk/uk-
tranfusion-committees/national-blood-transfusion-committee/patient-blood-
management June 2014.
[25] A. Kotzé, A. Harris, C. Baker, T. Iqbal, N. Lavies, T. Richards, et al., British committee
for standards in haematology guidelines on the identiﬁcation and management of
pre-operative anaemia, Br. J. Haematol. (Sep 6 2015), http://dx.doi.org/10.1111/
bjh.13623.
[26] A. Amato, M. Pescatori, Perioperative blood transfusions for the recurrence of colo-
rectal cancer, Cochrane Database Syst. Rev. 1 (Jan 25 2006), CD005033.
[27] T. Tonia, A. Mettler, N. Robert, G. Schwarzer, J. Seidenfeld, O.Weingart, et al., Eryth-
ropoietin or darbepoetin for patients with cancer, Cochrane Database Syst. Rev. 12
(Dec 12 2012) CD003407.
[28] K.F. Guenaga, D. Matos, P. Wille-Jorgensen, Mechanical bowel preparation for elec-
tive colorectal surgery, Cochrane Database Syst. Rev. (2011), CD001544.
[29] G.D. Toneva, R.J. Deierhoi, M. Morris, J. Richman, J.A. Cannon, L.K. Altom, et al., Oral
antibiotic bowel preparation reduces length of stay and readmissions after colorec-
tal surgery, J. Am. Coll. Surg. 216 (2013) 756–762 (discussion 762-3).
[30] F. Bretagnol, Y. Panis, E. Rullier, P. Rouanet, S. Berdah, B. Dousset, et al., Rectal can-
cer surgery with or without bowel preparation: the French GRECCAR III multicen-
ter single-blinded randomized trial, Ann. Surg. 252 (5) (2010 Nov) 863e8.
[31] A. Arnold, L.P. Aitchison, J. Abbott, Preoperative mechanical bowel preparation for
abdominal, laparoscopic, and vaginal surgery: a systematic review, J. Minim. Inva-
sive Gynecol. 22 (5) (2015) 737–752.
[32] K.L. Kantartzis, J.P. Shepherd, The use of mechanical bowel preparation in
laparoscopic gynecologic surgery: a decision analysis, Am. J. Obstet.
Gynecol. (2015), http://dx.doi.org/10.1016/j.ajog.2015.05.017 (pii: S0002-
9378(15)00480-9).
[33] N.A. Ryan, V.S. Ng, H. Sangi-Haghpeykar, X. Guan, Evaluating mechanical bowel
preparation prior to total laparoscopic hysterectomy, JSLS 19 (3) (2015), http://
dx.doi.org/10.4293/JSLS.2015.00035 (pii: e2015.00035).
[34] I. Smith, P. Kranke, I. Murat, A. Smith, G. O'Sullivan, E. Soreide, et al., Perioperative
fasting in adults and children: guidelines from the European Society of Anaesthe-
siology, Eur. J. Anaesthesiol. 28 (8) (2011) 556–569.
[35] M.D. Smith, J. McCall, L. Plank, G.P. Herbison, M. Soop, J. Nygren, Preoperative car-
bohydrate treatment for enhancing recovery after elective surgery, Cochrane Data-
base Syst. Rev. (8) (2014).
[36] J. Hausel, J. Nygren, A. Thorell, M. Lagerkranser, O. Ljungqvist, Randomized clinical
trial of the effects of oral preoperative carbohydrates on postoperative nausea and
vomiting after laparoscopic cholecystectomy, Br. J. Surg. 92 (4) (Apr 2005)
415–421.
[37] K.J. Walker, A.F. Smith, Premedication for anxiety in adult day surgery, Cochrane
Database Syst. Rev. 4 (2009), CD 002192.
[38] K. Matsuo, A.A. Yessaian, Y.G. Lin, H.Q. Pham, L.I. Muderspach, H.A. Liebman, et al.,
Predictive model of venous thromboembolism in endometrial cancer, Gynecol.
Oncol. 128 (3) (2013) 544–551.
[39] N. Levitan, A. Dowlati, S.C. Remick, H.I. Tahsildar, L.D. Sivinski, R. Beyth, et al., Rates
of initial and recurrent thromboembolic disease among patients with malignancy
versus those without malignancy. Risk analysis using medicare claims data, Medi-
cine (Baltimore) 78 (5) (1999) 285–291.
[40] S. Sweetland, J. Green, B. Liu, A. Berrington de González, M. Canonico, G. Reeves,
et al., Duration and magnitude of the postoperative risk of venous thromboembo-
lism in middle aged women: prospective cohort study, BMJ 339 (2009) b4583.
[41] C. Baykal, A. Al, E. Demirtas, A. Ayhan, Comparison of enoxaparin and standard
heparin in gynaecologic oncologic surgery: a randomised prospective double-
blind clinical study, Eur. J. Gynecol. Oncol. 22 (2) (2001) 127–130.
[42] G.H. Lyman, A.A. Khorana, N.M. Kuderer, A.Y. Lee, J.I. Arcelus, E.P. Balaban, et al., Ve-
nous thromboembolism prophylaxis and treatment in patients with cancer:
American Society of Clinical Oncology Clinical Practice guideline update, J. Clin.
Oncol. 31 (17) (2013) 2189–2204.
[43] J.M. Whitworth, K.E. Schneider, P.J. Frederick, M.A. Finan, E. Reed, J.M. Fauci, et al.,
Double prophylaxis for deep venous thrombosis in patients with gynecologic on-
cology who are undergoing laparotomy: does preoperative anticoagulation mat-
ter? Int. J. Gynecol. Cancer 21 (6) (2011) 1131–1134.
[44] T.T. Horlocker, D.J. Wedel, J.C. Rowlingson, F.K. Enneking, S.L. Kopp, H.T.
Benzon, et al., Regional anesthesia in the patient receiving antithrombotic or
thrombolytic therapy: American Society of Regional Anesthesia and Pain
Medicine Evidence-based guidelines (third edition), Reg. Anesth. Pain Med.
35 (1) (2010) 64–101.
[45] D.L. Clarke-Pearson, I.S. Synan, R. Dodge, J.T. Soper, A. Berchuck, R.E. Coleman, A
randomized trial of low-dose heparin and intermittent pneumatic calf
compression for the prevention of deep venous thrombosis after gynecologic
oncology surgery, Am. J. Obstet. Gynecol. 168 (4) (Apr 1993) 1146–1153
(discussion 1153–4).rative care in gynecologic/oncology surgery: Enhanced Recovery After
.1016/j.ygyno.2015.11.015
9G. Nelson et al. / Gynecologic Oncology xxx (2015) xxx–xxx[46] G.L. Maxwell, I. Synan, R. Dodge, B. Carroll, D.L. Clarke-Pearson, Pneumatic com-
pression versus low molecular weight heparin in gynecologic oncology surgery:
a randomized trial, Obstet. Gynecol. 98 (6) (Dec 2001) 989–995.
[47] M.H. Einstein, D.M. Kushner, J.P. Connor, A.A. Bohl, T.J. Best, M.D. Evans, et al., A
protocol of dual prophylaxis for venous thromboembolism prevention in gyneco-
logic cancer patients, Obstet. Gynecol. 112 (5) (Nov 2008) 1091–1097.
[48] J. Marjoribanks, C. Farquhar, H. Roberts, A. Lethaby, Long term hormone therapy for
perimenopausal women, Cochrane Database Syst. Rev. 7 (Jul 11 2012), CD004143.
[49] N. Panay, H. Hamoda, R. Arya, M. Savvas, The 2013 British Menopause Society and
Women's Health Concern recommendations on hormone replacement therapy,
Menopause Int. 19 (2) (Jun 2013) 59–68.
[50] NICE, Clinical Guideline 92. Reducing the risk of venous thromboembolism (deep
vein thrombosis and pulmonary embolism) in patients admitted to hospital,
www.nice.org.uk/cg92 2010.
[51] Venous Thromboembolism and Hormone Replacement Therapy, RCOG Green-top
Guideline No. 19, 3rd ed., 2011.
[52] V. Tanos, N. Rojansky, Prophylactic antibiotics in abdominal hysterectomy, J. Am.
Coll. Surg. 179 (5) (1994) 593–600.
[53] Bulletins–Gynecology, A.C.o.P., ACOG Practice Bulletin No. 104: antibiotic prophy-
laxis for gynecologic procedures, Obstet. Gynecol. 113 (5) (2009) 1180–1189.
[54] A. Gadducci, S. Cosio, N. Spirito, A.R. Genazzani, The perioperative management of
patients with gynaecological cancer undergoing major surgery: a debated clinical
challenge, Crit. Rev. Oncol. Hematol. 73 (2) (2010) 126–140.
[55] M.T. Hawn, J.S. Richman, C.C. Vick, R.J. Deierhoi, L.A. Graham, W.G. Henderson,
et al., Timing of surgical antibiotic prophylaxis and the risk of surgical site infec-
tion, JAMA Surg. 148 (7) (2013) 649–657.
[56] R.A. Forse, B. Karam, L.D. MacLean, N.V. Christou, Antibiotic prophylaxis for surgery
in morbidly obese patients, Surgery 106 (4) (1989) 750–756 discussion 756-7.
[57] S.M. Swoboda, C. Merz, J. Kostuik, B. Trentler, P.A. Lipsett, Does intraoperative
blood loss affect antibiotic serum and tissue concentrations? Arch. Surg. 131 (11)
(1996) 1165–1171 (discussion 1171-2).
[58] M.Y. Morrill, M.O. Schimpf, H. Abed, C. Carberry, R.U. Margulies, A.B. White, et al.,
Antibiotic prophylaxis for selected gynecologic surgeries, Int. J. Gynaecol. Obstet.
120 (1) (2013 Jan) 10–15.
[59] J. Webster, S. Osborne, Preoperative bathing or showering with skin antiseptics to
prevent surgical site infection, Cochrane Database Syst. Rev. 9 (2012), CD004985.
[60] J. Tanner, P. Norrie, K. Melen, Preoperative hair removal to reduce surgical site in-
fection, Cochrane Database Syst. Rev. 11 (2011), CD004122.
[61] R.O. Darouiche, M.J. Wall Jr., K.M. Itani, M.F. Otterson, A.L. Webb, M.M. Carrick,
et al., Chlorhexidine–alcohol versus povidone-iodine for surgical-site antisepsis,
N. Engl. J. Med. 362 (1) (2010) 18–26.
[62] B. Rocos, L.J. Donaldson, Alcohol skin preparation causes surgical ﬁres, Ann. R. Coll.
Surg. Engl. 94 (2) (2012) 87–89.
[63] R. Bailie, C. Craig, J. Restall, Total intravenous anesthesia for laparoscopy, Anaesthe-
sia 44 (1989) 60.
[64] M. Tramer, A. Moore, H. McQuay, Omitting nitrous oxide in general anaesthesia:
meta-analysis of intraoperative awareness and postoperative emesis in random-
ized controlled trials, Br. J. Anaesth. 76 (2) (Feb 1996) 186–193.
[65] C.C. Apfel, F.M. Heidrich, S. Jukar-Rao, L. Jalota, C. Hornuss, R.P. Whelan, et al.,
Evidence-based analysis of risk factors for postoperative nausea and vomiting,
Br. J. Anaesth. 109 (5) (Nov 2012) 742–753.
[66] Y. Punjasawadwong, A. Phongchiewboon, N. Bunchungmongkol, Bispectral index
for improving anaesthetic delivery and postoperative recovery, Cochrane Database
Syst. Rev. 6 (Jun 17 2014), CD003843.
[67] J. Guay, The beneﬁts of adding epidural analgesia to general anesthesia: a meta-
analysis, J. Anesth. 20 (2006) 335–340.
[68] E. Futier, J.M. Constantin, C. Paugam-Burtz, J. Pascal, M. Eurin, A. Neuschwander,
et al., A trial of intraoperative low-tidal-volume ventilation in abdominal surgery,
N. Engl. J. Med. 369 (2013) 428–437.
[69] T.J. Gan, P. Diemunsch, A.S. Habib, A. Kovac, P. Kranke, T.A. Meyer, et al., Consensus
guidelines for the management of postoperative nausea and vomiting, Anesth.
Analg. 118 (2014) 85–113.
[70] C.C. Apfel, E. Laara, M. Koivuranta, C.A. Greim, N. Roewer, A simpliﬁed risk score for
predicting postoperative nausea and vomiting: conclusions from cross-validations
between two centers, Anesthesiology 91 (1999) 693–700.
[71] C.C. Apfel, K. Korttila, M. Abdalla, H. Kerger, A. Turan, I. Vedder, et al., A factorial
trial of six interventions for the prevention of postoperative nausea and vomiting,
N. Engl. J. Med. 350 (2004) 2441–2451.
[72] S. Charlton, A.M. Cyna, P. Middleton, J.D. Grifﬁths, Perioperative transversus
abdominis plane (TAP) blocks for analgesia after abdominal surgery, Cochrane Da-
tabase Syst. Rev. 12 (2010) CD007705 (doi: CD007705).
[73] J.B. Carlisle, C.A. Stevenson, Drugs for preventing postoperative nausea and
vomiting, Cochrane Database Syst. Rev. 3 (2006), CD004125.
[74] A.S. Habib, H.E. El-Moalem, T.J. Gan, The efﬁcacy of the 5-HT3 receptor antagonists
combined with droperidol for PONV prophylaxis is similar to their combination
with dexamethasone. A meta-analysis of randomized controlled trials, Can. J.
Anaesth. 51 (2004) 311–319.
[75] P.H. Pan, S.C. Lee, L.C. Harris, Antiemetic prophylaxis for postdischarge nausea
and vomiting and impact on functional quality of living during recovery in
patients with high emetic risks: a prospective, randomized, double-blind com-
parison of two prophylactic antiemetic regimens, Anesth. Analg. 107 (2008)
429–438.
[76] P.J. Karanicolas, S.E. Smith, B. Kanbur, E. Davies, G.H. Guyatt, The impact of
prophylactic dexamethasone on nausea and vomiting after laparoscopic chole-
cystectomy: a systematic review and meta-analysis, Ann. Surg. 248 (2008)
751–762.Please cite this article as: G. Nelson, et al., Guidelines for pre- and intra-ope
Surgery (ERAS®) Society rec..., Gynecol Oncol (2015), http://dx.doi.org/10[77] T.J. Gan, T.A. Meyer, C.C. Apfel, F. Chung, P.J. Davis, A.S. Habib, et al., Society for Am-
bulatory Anesthesia guidelines for the management of postoperative nausea and
vomiting, Anesth. Analg. 105 (2007) 1615–1628.
[78] T.A. Meyer, C.R. Roberson, M.H. Rajab, J. Davis, C.H. McLeskey, Dolasetron versus
ondansetron for the treatment of postoperative nausea and vomiting, Anesth.
Analg. 100 (2005) 373–377.
[79] M. Orhan-Sungur, P. Kranke, D. Sessler, C.C. Apfel, Does supplemental oxygen
reduce postoperative nausea and vomiting? A meta-analysis of randomized con-
trolled trials, Anesth. Analg. 106 (2008) 1733–1738.
[80] U.H. Frey, P. Scharmann, C. Lohlein, J. Peters, P6 acustimulation effectively de-
creases postoperative nausea and vomiting in high-risk patients, Br. J. Anaesth.
102 (2009) 620–625.
[81] N. Reza, S.M. Ali, K. Saeed, A. Abul-Qasim, T.H. Reza, The impact of music on post-
operative pain and anxiety following cesarean section, Middle East J. Anesthesiol.
19 (2007) 573–586.
[82] L. Teran, J.K. Hawkins, The effectiveness of inhalation isopropyl alcohol vs.
granisetron for the prevention of postoperative nausea and vomiting, AANA J. 75
(2007) 417–422.
[83] C. Weilbach, K. Kahler, U. Thissen, N. Rahe-Meyer, S. Piepenbrock, Esomeprazole
for the prevention of postoperative nausea and vomiting. A randomized,
placebo-controlled trial, Eur. J. Anaesthesiol. 23 (2006) 338–340.
[84] E. Ernst, M.H. Pittler, Efﬁcacy of ginger for nausea and vomiting: a systematic
review of randomized clinical trials, Br. J. Anaesth. 84 (2000) 367–371.
[85] C. Czarnetzki, E. Schiffer, C. Lysakowski, G. Haller, D. Bertrand, M.R. Tramèr,
Transcutaneous nicotine does not prevent postoperative nausea and
vomiting: a randomized controlled trial, Br. J. Clin. Pharmacol. 71 (2011)
383–390.
[86] A. Obermair, J.M. Baker, S. Kondalsamy-Chennakesavan, A. Brand, R. Hogg, T.W.
Jobling, et al., Improved surgical safety after laparoscopic compared to open
surgery for apparent early stage endometrial cancer: results from a randomised
controlled trial, Eur. J. Cancer 48 (2012) 1147–1153.
[87] J.L. Walker, M.R. Piedmonte, N.M. Spirtos, S.M. Eisenkop, J.B. Schlaerth, et al.,
Laparoscopy compared with laparotomy for comprehensive surgical staging of
uterine cancer: Gynecologic Oncology Group Study LAP2, J. Clin. Oncol. 10
(2009) 5331–5336.
[88] B. Zand, M. Frumovitz, M.F. Jofre, A.M. Nick, R. Dos Reis, M.F. Munsell, et al., Risk
factors for prolonged hospitalization after gynecologic laparoscopic surgery,
Gynecol. Oncol. 126 (2012) 428–431.
[89] M.S. Vlug, J. Wind, M.W. Hollman, D.T. Ubbink, H.A. Cense, A.F. Engel, et al., Lapa-
roscopy in combination with fast track multimodal management is the best peri-
operative strategy in patients undergoing colonic surgery: a randomized clinical
trial (LAFA-study), Ann. Surg. 254 (2011) 868–875.
[90] S. Relph, A. Bell, V. Sivashanmugarajan, K. Munro, K. Chigwidden, S. Lloyd, et al.,
Cost effectiveness of enhanced recovery after surgery programme for vaginal hys-
terectomy: a comparison of pre and post-implementation expenditures, Int. J.
Health Plann. Manag. 29 (2014) 399–406.
[91] W. Yoong, V. Sivashanmugarajan, S. Relph, A. Bell, E. Fajemirokun, T. Davies, et al.,
Can enhanced recovery pathways improve outcomes of vaginal hysterectomy?
Cohort control study, J. Minim. Invasive Gynecol. 21 (2014) 83–89.
[92] M.L. Cheatham, W.C. Chapman, S.P. Key, J.L. Sawyers, A meta-analysis of selective
versus routine nasogastric decompression after elective laparotomy, Ann. Surg.
221 (5) (1995) 469–476 discussion 476-8.
[93] G. Cutillo, F. Maneschi, M. Franchi, R. Giannice, G. Scambia, P. Benedetti-Panici,
Early feeding compared with nasogastric decompression after major oncologic gy-
necologic surgery: a randomized study, Obstet. Gynecol. 93 (1) (1999) 41–45.
[94] Warttig S, Alderson P, Campbell G, Smith AF. Interventions for treating inadvertent
postoperative hypothermia. Warttig S. Cochrane Database Syst. Rev. Nov 20 2014;
11:CD009892. http://dx.doi.org/10.1002/14651858.CD009892.pub2.
[95] E.M. Scott, R. Buckland, A systematic review of intraoperative warming to prevent
postoperative complications, AORN J. 83 (5) (2006 May) 1090 –104–1107–13.
[96] S. Rajagopalan, E. Mascha, J. Na, D.I. Sessler, The effects of mild perioperative hypo-
thermia on blood loss and transfusion requirement, Anesthesiology (2008).
[97] P.F. Wong, S. Kumar, A. Bohra, D. Whetter, D.J. Leaper, Randomized clinical trial of
perioperative systemic warming in major elective abdominal surgery, Br. J. Surg.
94 (4) (2007 Apr 1) 421–426 (John Wiley & sons, Ltd.).
[98] C.M. Galvão, Y. Liang, A.M. Clark, Effectiveness of cutaneous warming systems on
temperature control: meta analysis, J. Adv. Nurs. 66 (6) (Jun 1 2010) 1196–1206
(Blackwell Publishing Ltd.).
[99] S. Perez-Protto, D.I. Sessler, L.F. Reynolds, M.H. Bakri, E. Mascha, J. Cywinski, et al.,
Circulating-water garment or the combination of a circulating-water mattress and
forced-air cover to maintain core temperature during major upper-abdominal sur-
gery, Br. J. Anaesth. 105 (4) (Oct 2010) 466–470 (Oxford University Press).
[100] G. Campbell, P. Alderson, A.F. Smith, S. Warttig, in: G. Campbell (Ed.), Warming of
Intravenous and Irrigation Fluids for Preventing Inadvertent Perioperative Hypo-
thermia, Chichester, UK, John Wiley & Sons, Ltd., 2012
[101] K. Raghunathan, M. Singh, D.N. Lobo, Fluid management in abdominal surgery:
what, when, and when not to administer, Anesthesiol. Clin. 33 (1) (Mar 2015)
51–64.
[102] D.N. Lobo, K.A. Bostock, K.R. Neal, A.C. Perkins, B.J. Rowlands, S.P. Allison, Effect of
salt and water balance on recovery of gastrointestinal function after elective colon-
ic resection: a randomised controlled trial, Lancet 359 (9320) (May 25 2002)
1812–1818 (Elsevier).
[103] B. Brandstrup, H. Tonnesen, R. Beier-Holgersen, E. Hjortso, H. Ording, K. Lindorff-
Larsen, et al., Effects of intravenous ﬂuid restriction on postoperative complica-
tions: comparison of two perioperative ﬂuid regimens: a randomized assessor-
blinded multicenter trial, Ann. Surg. 238 (2003) 641–648.rative care in gynecologic/oncology surgery: Enhanced Recovery After
.1016/j.ygyno.2015.11.015
10 G. Nelson et al. / Gynecologic Oncology xxx (2015) xxx–xxx[104] N.N. Rahbari, J.B. Zimmermann, T. Schmidt, M. Koch, M.A. Weigand, J. Weitz, Meta-
analysis of standard, restrictive and supplemental ﬂuid administration in colorectal
surgery, Br. J. Surg. 96 (2009) 331–341.
[105] P.E. Marik, R. Cavallazzi, T. Vasu, A. Hirani, Dynamic changes in arterial waveform
derived variables and ﬂuid responsiveness in mechanically ventilated patients: a
systematic review of the literature, Crit. Care Med. 37 (9) (Sep 2009) 2642–2647.
[106] A. Feldheiser, O. Hunsicker, H. Krebbel, K. Weimann, L. Kaufner, K.-D.
Wernecke, et al., Oesophageal Doppler and calibrated pulse contour analysis
are not interchangeable within a goal-directed haemodynamic algorithm in
major gynaecological surgery, Br. J. Anaesth. 113 (5) (Nov 2014) 822–831
(Oxford University Press).
[107] M. McKenny, P. Conroy, A. Wong, M. Farren, N. Gleeson, C. Walsh, et al., A
randomised prospective trial of intra-operative oesophageal Doppler-guided
ﬂuid administration in major gynaecological surgery, Anaesthesia 68 (12) (2013
Dec) 1224–1231.Please cite this article as: G. Nelson, et al., Guidelines for pre- and intra-ope
Surgery (ERAS®) Society rec..., Gynecol Oncol (2015), http://dx.doi.org/10[108] S. Chattopadhyay, S. Mittal, S. Christian, A.L. Terblanche, A. Patel, I. Biliatis, et al.,
The role of intraoperative ﬂuid optimization using the esophageal Doppler in ad-
vanced gynecological cancer: early postoperative recovery and ﬁtness for dis-
charge, Int. J. Gynecol. Cancer 23 (1) (2013 Jan 1) 199–207.
[109] G. Minto, M.J. Scott, T.E. Miller, Monitoring needs and goal-directed ﬂuid therapy
within an enhanced recovery program, Anesthesiol. Clin. 33 (1) (2015Mar) 35–49.
[110] C. Challand, R. Struthers, J.R. Sneyd, P.D. Erasmus, N. Mellor, K.B. Hosie, et al.,
Randomized controlled trial of intraoperative goal-directed ﬂuid therapy in aero-
bically ﬁt and unﬁt patients having major colorectal surgery, Br. J. Anaesth. 108
(1) (Jan 2012) 53–62 (Oxford University Press).
[111] M.A. Hamilton, M. Cecconi, A. Rhodes, A systematic review and meta-analysis on
the use of preemptive hemodynamic intervention to improve postoperative
outcomes in moderate and high-risk surgical patients, Anesth. Analg. 112 (6)
(Jun 2011) 1392–1402.rative care in gynecologic/oncology surgery: Enhanced Recovery After
.1016/j.ygyno.2015.11.015
